Psoriatic arthritis and psoriasis: Need for a multidisciplinary approach

Seminars in Cutaneous Medicine and Surgery

Volumn 24, Issue 1, 2005, Pages 46-51

  Qureshi, Abrar A ^a   Husni, M Elaine ^a   Mody, Elinor ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIMALARIAL AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FOLIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; INFLUENZA VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; RETINOID; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ARTHROPATHY; BONE MARROW TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; ERYTHRODERMA; EVALUATION; FOLLOW UP; GOUT; HUMAN; INFLAMMATION; JOINT DESTRUCTION; JOINT STABILITY; LIVER FIBROSIS; LIVER TOXICITY; OSTEOARTHRITIS; PATIENT; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PNEUMONIA; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SCREENING;

ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; HUMANS; PATIENT CARE TEAM; PHOTOTHERAPY; PSORIASIS;

EID: 15744396299     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2005.01.006     Document Type: Review

References (25)

1. R.S. Stern The epidemiology of joint complaints in patients with psoriasis J Rheumatol 12 1985 315 320
2. D.J. Veale, O. FitzGerald Psoriatic arthritis-pathogenesis and epidemiology Clin Exp Rheumatol 20 suppl 2002 S27 S33
3. J. Thumboo, K. Uramoto, M.I. Shbeeb Risk factors for the development of psoriatic arthritis a population based nested case control study J Rheumatol 29 2002 757 762
4. E.M. Ruderman, S. Tambar Psoriatic arthritis Prevalence, diagnosis, and review of therapy for the dermatologist Dermatol Clin 22 2004 477 486
5. W.J. Taylor Epidemiology of psoriatic arthritis Curr Opin Rheumatol 14 2002 98 103
6. D.J. Veale The epidemiology of psoriatic arthritis Fact or fiction? [see comment] J Rheumatol 27 2000 1105 1106
7. T. O'Neill, A.J. Silman Psoriatic arthritis. Historical background and epidemiology Baillieres Clin Rheumatol 8 1994 245 261
8. H. Galadari, B. Fuchs, M. Lebwohl Newly available treatments for psoriatic arthritis and their impact on skin psoriasis Int J Dermatol 42 2003 231 237
9. H. Zachariae Prevalence of joint disease in patients with psoriasis Implications for therapy Am J Clin Dermatol 4 2003 441 447
10. A.P. Anandarajah, C.T. Ritchlin Etanercept in psoriatic arthritis Expert Opinion Biol Ther 3 2003 169 177
11. S.P. McKenna Development of the PsAQoL a quality of life instrument specific to psoriatic arthritis Ann Rheum Dis 63 2004 162 169
12. K.B. Sokoll, P.S. Helliwell Comparison of disability and quality of life in rheumatoid and psoriatic arthritis J Rheumatol 28 2001 1842 1846
13. W.J. Taylor Assessment of outcome in psoriatic arthritis Curr Opin Rheumatol 16 2004 350 356
14. P.J. Mease Recent advances in the management of psoriatic arthritis Curr Opin Rheumatol 16 2004 366 370
15. G.A. Slagel, W.D. James Plaquenil-induced erythroderma J Am Acad Dermatol 12 1985 857 862
16. J.E. Vine Pustular psoriasis induced by hydroxychloroquine A case report and review of the literature J Dermatol 23 1996 357 361
17. Q.E. Whiting-O'Keefe, K.H. Fye, K.D. Sack Methotrexate and histologic hepatic abnormalities A meta-analysis Am J Med 90 1991 711 716
18. J.K. Robinson Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals Arch Dermatol 116 1980 413 415
19. H. Zachariae, L. Heickendorff, H. Sogaard The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis A 10-year follow-up Br J Dermatol 144 2001 100 103
20. A.Y. Goedkoop Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis Ann Rheum Dis 63 2004 769 773
21. N. Scheinfeld Adalimumab (HUMIRA) A review J Drugs Dermatol 2 2003 375 377
22. M.C. Kraan Alefacept treatment in psoriatic arthritis Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis Arthritis Rheumatism 46 2002 2776 2784
23. J. Braun, J. Sieper Role of novel biological therapies in psoriatic arthritis Effects on joints and skin Biodrugs 17 2003 187 199
24. C. Vahlquist Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation Arthritis Rheum 39 1996 1519 1523
25. D.D. Gladman Longitudinal study of clinical and radiological progression in psoriatic arthritis J Rheumatol 17 1990 809 812